Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based biotech company, PolyTherics, has acquired Warwick Effect Polymers (WEP), a provider of specialty biopolymers for the modification of biological products.
Subscribe to our email newsletter
WEP has developed two proprietary biopolymer technologies, PolyPEG and GlycoPol, and the company plans to license deals for these technologies this year.
WEP’s PolyPEG is a low viscosity comb polymer for extending the duration of action of biopharmaceuticals and GlycoPol is a novel glycopolymer for targeting the delivery of therapeutic agents to specific glycan receptors on cells.
PolyTherics’ proprietary conjugation technologies, TheraPEG, CyPEG and HiPEG, have been used to attach polymers to specific sites on proteins and peptides to extend their duration of action and to produce antibody drug conjugates.
PolyTherics CEO John Burt said the acquisition allows the combined businesses to provide a portfolio of best-in-class technologies to enable better biopharmaceuticals, benefiting patients.